CN102108096A - 一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法 - Google Patents

一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法 Download PDF

Info

Publication number
CN102108096A
CN102108096A CN 200910256418 CN200910256418A CN102108096A CN 102108096 A CN102108096 A CN 102108096A CN 200910256418 CN200910256418 CN 200910256418 CN 200910256418 A CN200910256418 A CN 200910256418A CN 102108096 A CN102108096 A CN 102108096A
Authority
CN
China
Prior art keywords
interferon
chicken
gamma
escherichia coli
chicken alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 200910256418
Other languages
English (en)
Inventor
郝智慧
宋丽
贾德强
张瑞丽
邱梅
王春元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QINGDAO LIUHE MEDICINE CO Ltd
QINGDAO CONTINENT BIOTECH CO Ltd
Qingdao Continent Pharmaceutical Co Ltd
Original Assignee
QINGDAO LIUHE MEDICINE CO Ltd
QINGDAO CONTINENT BIOTECH CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QINGDAO LIUHE MEDICINE CO Ltd, QINGDAO CONTINENT BIOTECH CO Ltd filed Critical QINGDAO LIUHE MEDICINE CO Ltd
Priority to CN 200910256418 priority Critical patent/CN102108096A/zh
Publication of CN102108096A publication Critical patent/CN102108096A/zh
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明涉及一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法。本发明的目的在于提供一种抗肿瘤效果好、提高畜禽免疫力的,能够在短时间内实现控制病情的干扰素。其组分为:大肠杆菌重组鸡α-扰素、大肠杆菌鸡γ-干扰素;其制备方法为:基因设计,表达载体构建,诱导表达,目的蛋白质纯化及活性检测即得。该药品为畜禽病毒病治疗替代药物,利用大肠杆菌表达鸡α-扰素、鸡γ-干扰素,具有广谱的抗病毒作用。通过纯化蛋白后具有免疫调节活性和一定的抗病毒活性,二者联合应用于临床具有明显的协同作用。本发明制成的二价干扰素可优于单独应用任何一种干扰素对新城疫和法氏囊病的治疗和预防效果。

Description

一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法
技术领域
本发明涉及一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法。
背景技术
当前家禽肿瘤病和病毒病感染引起的鸡马立克氏病、新城疫、传染性法氏囊病、传染性支气管炎、传染性喉气管炎、脑脊髓炎、流感、传染性贫血、病毒性肝炎等病毒病给养禽业带来巨大的经济损失,今年来已经成为危害鸡业最为严重的疾病之一。对家禽肿瘤病和病毒病的有效治疗一直是困扰禽病防治的重大难题之一。鸡的免疫***以及在病原感染或注射疫苗时所产生的免疫反应与PURU动物相似,所以可以考虑应用细胞因子来控制疾病。相对来说,禽类的饲养简单、廉价,出笼时间短,而且数量较大,这就需要考虑所用疫苗或者治疗药物的经济价值。绿色食品工程的启动,人们对食品安全的重视的升温,常用抗病毒药物带来的严重的药物残留危及人类的健康,这些问题得到社会的普遍关注。所以,养禽业迫切需要新一代的天然治疗方法。在病原感染和疫苗免疫中,干扰素等细胞因子可调控免疫反应的类型与反应强度,是一种高效的、天然的治疗方法。而按照传统方法进行治疗,很难在短时间内控制病情,而使用基因工程干扰素则可以使机体迅速的抗病毒增殖,抗肿瘤增生,并能提高免疫力。在临床上应用,不但效果明显,而且无药物残留,能在病毒性感染的早期对其进行有效的治疗。利用生物技术手段研制开发畜禽用干扰素(IFN)是在化学药物禁用后抵抗畜禽疫病有力武器,IFN具有广谱的抗病毒作用,表现在毒增殖量减少,细胞损伤程度降低,同时具有提高机体免疫力的双重作用。可用于防治鸡新城疫、禽流感、法氏囊病。本发明选择干扰素的基因工程表达产物开发出绿色高效抗感染生物制剂,实现基因工程表达干扰素产品产业化。
本发明涉及的一种重组鸡α-γ二价干扰素具有抗病毒和免疫调节的双重功效,未见临床联合应用的报道。
发明内容
1、根据GenBank中鸡IFN-α基因设计引物对,利用PCR技术克隆,在成熟肽基因两侧设计一对引物,分别加入合适的酶切位点,将其亚克隆在表达载体PET上,转化BL21(DE3)后用IPTG诱导表达,用SDS-PAGE电泳分析表达形式,结果为蛋白以包涵体形式表达,破碎菌体提取包涵体纯化后,利用半胱胺酸-半胱胺酸再氧化法对纯化后的包涵体变性液进行分段稀释法复性。通过细胞病变抑制法测定复性液体的抗病毒活性,得到鸡α-干扰素。
2、根据GenBank中鸡IFN-γ基因序列,去掉信号肽区,对其成熟肽区进行大肠杆菌密码子偏好性改造和mRNAde 5’端耳机结构进行分析,在序列两端同时设立BgI II与Hand III酶切位点,进行合成和TA克隆测序验证。再经过表达载体的构建、重组表达载体的转化、诱导表达,在经过电泳后确定表达形式,通过镍柱纯化目的蛋白并抗病毒活性检测,最后得到了鸡γ-干扰素。
3、通过基因设计与合成,表达子载体的构建、诱导表达、目的蛋白纯化及获得活性物质而制成。将鸡α-干扰素和鸡γ-干扰素成熟基因克隆至PET载体上,转化至宿主菌BL21(DE3)中,经IPTG诱导表达,得到了目的蛋白,经过水泡性口炎病毒-鸡胚成纤维细胞***测定具有很高的抗病毒活性。
本发明的优点在于利用大肠杆菌表达鸡α-干扰素,以包涵体形式表达,通过变性复性后具有广谱的抗病毒作用,而大肠杆菌表达鸡γ-干扰素分泌表达,通过纯化蛋白后具有免疫调节活性和一定的抗病毒活性,二者联合应用具有明显的协同作用,本发明所得二价干扰素可优于单独应用任何一种干扰素对新城疫和法氏囊的治疗和预防。
具体实施方式
根据GenBank中鸡IFN-α基因设计引物对,利用PCR技术克隆IFN-α基因,在成熟肽基因两侧设计一对引物,分别加入合适的酶切位点,将其亚克隆在表达载体PET上,转化BL21(DE3)后用IPTG诱导表达,用SDS-PAGE电泳分析表达形式,结果为蛋白以包涵体形式表达,破碎菌体提取包涵体纯化后,利用半胱胺酸-半胱胺酸再氧化法对纯化后的包涵体变性液进行分段稀释法复性。通过细胞病变抑制法测定复性液体的抗病毒活性,得到鸡α-干扰素。再根据GenBank中鸡IFN-γ基因序列,去掉信号肽区,对其成熟肽区进行大肠杆菌密码子偏好性改造和mRNAde 5’端耳机结构进行分析,在序列两端同时设立BgI II与Hand III酶切位点,进行合成和TA克隆测序验证。再经过表达载体的构建、重组表达载体的转化、诱导表达,在经过电泳后确定表达形式,通过镍柱纯化目的蛋白并抗病毒活性检测,最后得到了鸡α-γ干扰素。

Claims (3)

1.一种大肠杆菌重组鸡α-γ二价干扰素,其特征在于其主要成分为大肠杆菌重组鸡α-γ二价干扰素,为无色至微黄的澄明液体,无肉眼可见不溶物。
2.根据权利要求1所述的一种大肠杆菌重组鸡α-γ二价干扰素,其特征在用大肠杆菌表达的鸡α-干扰素和鸡γ-干扰素制成二价干扰素。
3.根据权利要求2所述的一种大肠杆菌重组鸡α-γ二价干扰素的制备方法,其特征在于:通过基因设计与合成,表达子载体的构建、诱导表达、目的蛋白纯化及获得活性物质而制成。将鸡α-干扰素和鸡γ-干扰素成熟基因克隆至PET载体上,转化至宿主菌BL21(DE3)中,经IPTG诱导表达,得到了目的蛋白,经过水泡性口炎病毒-鸡胚成纤维细胞***测定具有很高的抗病毒活性。
CN 200910256418 2009-12-25 2009-12-25 一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法 Pending CN102108096A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200910256418 CN102108096A (zh) 2009-12-25 2009-12-25 一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200910256418 CN102108096A (zh) 2009-12-25 2009-12-25 一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法

Publications (1)

Publication Number Publication Date
CN102108096A true CN102108096A (zh) 2011-06-29

Family

ID=44172390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200910256418 Pending CN102108096A (zh) 2009-12-25 2009-12-25 一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法

Country Status (1)

Country Link
CN (1) CN102108096A (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103585628A (zh) * 2013-11-21 2014-02-19 青岛润达生物科技有限公司 一种治疗鸡新城疫病的免疫球蛋白制剂及其制备方法
CN108576399A (zh) * 2018-03-22 2018-09-28 中国农业科学院生物技术研究所 复合干扰素组合物及其制剂和应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103585628A (zh) * 2013-11-21 2014-02-19 青岛润达生物科技有限公司 一种治疗鸡新城疫病的免疫球蛋白制剂及其制备方法
CN103585628B (zh) * 2013-11-21 2016-08-17 青岛润达生物科技有限公司 一种预防鸡新城疫病的免疫球蛋白制剂及其制备方法
CN108576399A (zh) * 2018-03-22 2018-09-28 中国农业科学院生物技术研究所 复合干扰素组合物及其制剂和应用

Similar Documents

Publication Publication Date Title
CN102041263B (zh) 鸡α干扰素/白细胞介素2嵌合基因
Seal et al. Alternatives to antibiotics: a symposium on the challenges and solutions for animal production
Meng et al. Recombinant chicken interferon-α inhibits H9N2 avian influenza virus replication in vivo by oral administration
AU2006210753B2 (en) Method and use of interferon compositions for the treatment of avian influenza
JP5209462B2 (ja) コンセンサスインターフェロンの使用方法
CN104447978A (zh) 重组鸡干扰素α及其制备方法
Ohta et al. Anti-viral effects of interferon administration on sevenband grouper, Epinephelus septemfasciatus
Rehman et al. Interaction of infectious bursal disease virus with the immune system of poultry
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
Kalenik et al. Β-defensins–Underestimated peptides in influenza combat
Parhi et al. Molecular characterization and expression analysis of interferon γ (IFN-γ) gene in Labeo rohita (Ham.)
Li et al. Antiviral activity of porcine interferon delta 8 against foot-and-mouth disease virus in vitro
CN102108096A (zh) 一种大肠杆菌重组鸡α-γ二价干扰素及其制备方法
Guo et al. Molecular cloning and characterization of a novel bovine IFN-ε
EP4121092B1 (en) Hybrid interferons for treating viral infections
CN101798350A (zh) 人干扰素α-2b与人胸腺素α1的融合蛋白及其制备
Cai et al. Expression and purification of chicken beta interferon and its antivirus immunological activity
Zhang et al. Type III interferon gene expression in response to influenza virus infection in chicken and duck embryonic fibroblasts
Wang et al. Cloning and codon optimization of a novel feline interferon omega gene for production by Pichia pastoris and its antiviral efficacy in polyethylene glycol-modified form
CN109134641A (zh) 一种鸡干扰素-α的制备方法
CN101612389B (zh) 一种禽畜用抗病毒组合物
Stebbing et al. Antiviral effects of bacteria-derived human leukocyte interferons against encephalomyocarditis virus infection of squirrel monkeys
Gao et al. Recombinant duck interferon gamma inhibits H5N1 influenza virus replication in vitro and in vivo
CN101351218A (zh) 干扰素组合物用于治疗禽流感的方法和用途
Anjum et al. Antiviral potential and stability analysis of chicken interferon-α produced by Newcastle disease virus in chicken embryo fibroblast cells.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent for invention or patent application
CB02 Change of applicant information

Address after: 266000 Shandong city of Qingdao province Chengyang Qingda Industrial Park, the first northbound dual

Applicant after: Qingdao KDN Pharmaceutical Co., Ltd.

Applicant after: Qingdao Conlinent Animal Pharmaceutical Co., Ltd.

Address before: 266061 Shandong city of Qingdao province high tech park of Laoshan district by the No. 29 Shandong Road, building 605 high speed

Applicant before: Qingdao Continent Biotech Co., Ltd.

Applicant before: Qingdao Liuhe Medicine Co., Ltd.

CB03 Change of inventor or designer information

Inventor after: Wang Lei

Inventor after: Wang Honghua

Inventor after: Ling Hongli

Inventor after: Jia Deqiang

Inventor before: Hao Zhihui

Inventor before: Song Li

Inventor before: Jia Deqiang

Inventor before: Zhang Ruili

Inventor before: Qiu Mei

Inventor before: Wang Chunyuan

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: HAO ZHIHUI SONG LI JIA DEQIANG ZHANG RUILI QIU MEI WANG CHUNYUAN TO: WANG LEI WANG HONGHUA LING HONGLI JIA DEQIANG

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110629